Evidence map›Paper›PMID 28900792›Full record

ArticleJournal of computer-aided molecular design2018

Relative binding affinity prediction of farnesoid X receptor in the D3R Grand Challenge 2 using FEP.

Christina Schindler, Friedrich Rippmann, Daniel Kuhn

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of computer-aided molecular design, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Christina SchindlerComputational Chemistry and Biology, Merck KGaA, Darmstadt, Germany. christina.schindler@merckgroup.com.
Friedrich RippmannComputational Chemistry and Biology, Merck KGaA, Darmstadt, Germany.
Daniel KuhnComputational Chemistry and Biology, Merck KGaA, Darmstadt, Germany.
Merck (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Physics-based free energy simulations have increasingly become an important tool for predicting binding affinity and the recent introduction of automated protocols has also paved the way towards a more widespread use in the pharmaceutical industry. The D3R 2016 Grand Challenge 2 provided an opportunity to blindly test the commercial free energy calculation protocol FEP+ and assess its performance relative to other affinity prediction methods. The present D3R free energy prediction challenge was built around two experimental data sets involving inhibitors of farnesoid X receptor (FXR) which is a promising anticancer drug target. The FXR binding site is predominantly hydrophobic with few conserved interaction motifs and strong induced fit effects making it a challenging target for molecular modeling and drug design. For both data sets, we achieved reasonable prediction accuracy (RMSD ≈ 1.4 kcal/mol, rank 3-4 according to RMSD out of 20 submissions) comparable to that of state-of-the-art methods in the field. Our D3R results boosted our confidence in the method and strengthen our desire to expand its applications in future in-house drug design projects.

Indexed as

Drug DesignMolecular Docking SimulationThermodynamicsBinding SitesComputer-Aided DesignHumansLigandsProtein BindingProtein ConformationReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearSmall Molecule LibrariesLigandsReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearSmall Molecule LibrariesBinding affinity predictionComputer-aided drug designD3RDrug design data resourceFree energy calculations

Identifiers

PMID28900792
OpenAlexW2755656231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.